Stockscreener 앱 받기
1.36
9.93%
-0.15
시간 외 거래:
1.43
0.07
+5.15%
Tenax Therapeutics Inc 주식(TENX)의 최신 뉴스
TENX Stock Drifts Lower As Traders Eye Cash Runway - StocksToTrade
TENX Stock Drifts Lower As Traders Watch Tight Range - Timothy Sykes
Sphera Funds Management Discloses 7.09% Stake in Tenax Therapeutics as of September 2026 - Kalkine Media
Call option shares count toward Sphera’s amended stake disclosure in Tenax Therapeutics (TENX). - Stock Titan
EBIT per share of Tenax Therapeutics, Inc. – HAM:YBO0 - TradingView
A 2.4M-share position in Tenax Therapeutics (TENX) is reported with no sole voting power. - Stock Titan
Tenax Therapeutics To Amend Level-2 Enrollment Criteria - TradingView
Tenax Therapeutics pauses LEVEL-2 enrollment to implement enrichment after Phase 3 LEVEL learnings - TradingView
Tenax Therapeutics, Inc. Provides Update on Tnx-103 Level and Level-2 Clinical Trials - www.marketscreener.com
Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Investing News Network
Wall Street Analysts Predict a 121.36% Upside in Tenax Therapeutics (TENX): Here's What You Should Know - Eastern Progress
Independent Director of Tenax Therapeutics Declan Doogan Buys 2,331% More Shares - webull.com
Tenax Therapeutics, Inc.(NasdaqCM: TENX) added to S&P Global BMI Index - marketscreener.com
Director Declan Doogan Buys 53,000 Shares of Tenax Therapeutics Inc (TENX) - GuruFocus
ING Groep NV Exits Tenax Therapeutics Inc (TENX) Position in Ful - GuruFocus
Tenax Therapeutics CFO buys $10,981 in common stock - Investing.com
ING Groep reports zero stake in Tenax Therapeutics (TENX) - Stock Titan
Tenax Therapeutics Stock Short Interest Rises to 35.39% - Quiver Quantitative
Cantor Fitzgerald reiterates Tenax Therapeutics stock rating at overweight By Investing.com - Investing.com South Africa
Cantor Fitzgerald reiterates Tenax Therapeutics stock rating at overweight By Investing.com - Investing.com Canada
Tenax at Cantor conference: trial miss sharpens next-step strategy By Investing.com - Investing.com India
Tenax at Cantor conference: trial miss sharpens next-step strategy By Investing.com - Investing.com UK
Tenax Therapeutics Updates Phase 3 LEVEL Trial Strategy - tipranks.com
Adar1 Capital Management, 10% owner, buys $1.6m in Tenax Therapeutics - Investing.com Australia
Adar1 Capital Management, 10% owner, buys $1.6m in Tenax Therapeutics By Investing.com - Investing.com South Africa
Adar1 Capital Management, 10% owner, buys $1.6m in Tenax Therapeutics - Investing.com Nigeria
Adar1 Capital Management, 10% owner, buys $1.6m in Tenax Therapeutics By Investing.com - Investing.com South Africa
Adar1 Capital Management, 10% owner, buys $1.6m in Tenax Therapeutics - Investing.com Canada
Adar1 Capital Management, 10% owner, buys $1.6m in Tenax Therapeutics - Investing.com
ADAR1 Capital Management, LLC Expands Tenax Therapeutics Inc (TE - GuruFocus
One manager just reported a 14% holding in Tenax Therapeutics (TENX) - Stock Titan
FMR LLC reports 514,925-share stake in Tenax (NASDAQ: TENX) - Stock Titan
TENX Jumps As Tenax Therapeutics Pivots Phase 3 Strategy - timothysykes.com
Tenax Therapeutics Stock Wobbles After Mixed Phase 3 Data - timothysykes.com
Tenax (TENX) Found a 26.3-Meter Benefit in a Prespecified Subgroup After LEVEL Missed Its Primary Endpoint. Is Another Phase 3 Trial Viable? - Yahoo Finance
Sphera Funds Management Boosts Tenax Therapeutics Stake in High-Risk Biotech Bet - GuruFocus
Investment funds tied to Tenax (TENX) 10% owner just bought more stock - Stock Titan
Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference - Stock Titan
Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference - GlobeNewswire
Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference - finance.yahoo.com
TENX Downgraded by Guggenheim -- Rating Updated to Neutral - GuruFocus
Piper Sandler Maintains Tenax Therapeutics(TENX.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Guggenheim Downgrades TENX to Neutral Amid Uncertain Clinical Ou - GuruFocus
Why is Tenax Therapeutics stock volatile today? By Investing.com - Investing.com Canada
Why is Tenax Therapeutics stock volatile today? By Investing.com - Investing.com UK
Tenax Therapeutics (TENX) Phase 3 Data Spurs Focus on Subgroup B - GuruFocus
Tenax finds benefit in sicker patient subgroup after Phase 3 trial miss (TENX:NASDAQ) - Seeking Alpha
Tenax presents additional Phase 3 trial data for TNX-103 By Investing.com - Investing.com Nigeria
Tenax presents additional Phase 3 trial data for TNX-103 By Investing.com - Investing.com India
Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026 - Investing News Network
4.22%
자본화:
|
볼륨(24시간):